Hyperphosphatemia, or elevated serum phosphorus, is common in dialysis patients and tightly linked to the progression of SHPT.

Hyperphosphatemia, or elevated serum phosphorus, is common in dialysis patients and tightly linked to the progression of SHPT and vascular

The kidney plays an important role in the regulation of phosphate, including the control of tubular reabsorption of phosphorus in the effect of parathyroid hormone.

Low levels of serum phosphate cause rickets, which is worsened by decreased proximal tubular conversion of vitamin D to its active form.

There were no differences in mean serum calcium, phosphate, or 24-hour urine calcium between treatment groups.

There were no differences in mean serum calcium, phosphate, or 24-hour urine calcium between treatment groups.

There were no differences in mean serum calcium, phosphate, or 24-hour urine calcium between treatment groups.

Although an increase in azotemia, serum potassium and phosphoremia can be observed initially, it is due to the recovery of the appetite in asthenic and malnourished patients.

However, the incidence of reductions in serum calcium to < 2.0 mmol/l and serum phosphate to ≤ 0.65 mmol/l was comparable in the two groups.

Laboratory tests found calcemy at 2,33 mmol/L, phosphoremy at 3,1 mmol/L, parathyroid hormone (PTH) at 770 ng/L and creatinine at 977 mol/L. The patient was offered a surgical procedure but he refused it.

Alpharen™ has been shown safe and effective in treating hyperphosphatemia in the phase 2 and 3 clinical trials undertaken to date in dialysis patients.